GnRH Agonist Versus hCG Trigger in Ovulation Induction With Intrauterine Insemination.

What Was Tested

The trial (not phased) is built around hCG (human chorionic gonadotropin).

This study aims to compare clinical pregnancy rates (CPR) in patients who are administered either Gonadotropin-releasing hormone agonists (GnRHa) or human chorionic gonadotropin (hCG) for ovulation trigger in intrauterine insemination (IUI) cycles.

Total of 197 infertile women were randomly assigned to receive either GnRHa trigger (n=98 cycles) or hCG trigger (n= 99 cycles) for ovulation trigger.

It had two arms (groups): GnRHa trigger (experimental) and hCG trigger (experimental).

The registry classes the interventions as drug.

More on the Plan

Study population A total of 217 women were recruited into the sample at the first stage.

Inclusion criteria were women with bilateral tubal patency, at least one follicle ≥ 18mm in diameter on the day of trigger, and men with more than five millions total motile sperm after preparation.

Patients were randomly assigned to receive either GnRHa trigger (n=98 cycles) or hCG trigger (n= 99 cycles) for ovulation trigger.

Intervention All patients included in the study were subjected to complete history and physical.

Who Took Part

The registry lists 197 actual participants took part.

It was open to women only aged from 18 years up to 45 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Infertile women who were indicated for IUI cycles. Bilateral tubal patency. At least one follicle ≥ 18mm in diameter on the day of trigger, and. Men with more than five millions total motile sperm after preparation.

The full record lists 5 inclusion and 2 exclusion criteria; among the exclusions: no mature follicle; disagree to be enrolled.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

The participants were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

The hCG (human chorionic gonadotropin) group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received hCG (human chorionic gonadotropin).

Those kept unaware of assignments: participant and investigator.

It started in 2016-04-01 with completion listed for 2017-06-30.

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of hCG (human chorionic gonadotropin) in 197 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.